These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 31674269)
1. The potential of ctDNA analysis in breast cancer. Tzanikou E; Lianidou E Crit Rev Clin Lab Sci; 2020 Jan; 57(1):54-72. PubMed ID: 31674269 [TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Croessmann S; Park BH Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964 [TBL] [Abstract][Full Text] [Related]
3. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187 [TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634 [TBL] [Abstract][Full Text] [Related]
5. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer. Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313 [TBL] [Abstract][Full Text] [Related]
6. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA. Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100 [TBL] [Abstract][Full Text] [Related]
7. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182 [TBL] [Abstract][Full Text] [Related]
8. Genetic profiling of cancer with circulating tumor DNA analysis. Lu L; Bi J; Bao L J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957 [TBL] [Abstract][Full Text] [Related]
9. Review ctDNA and Breast Cancer. Clatot F Recent Results Cancer Res; 2020; 215():231-252. PubMed ID: 31605232 [TBL] [Abstract][Full Text] [Related]
10. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585 [TBL] [Abstract][Full Text] [Related]
11. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma. Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033 [TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy: unlocking the potentials of cell-free DNA. Chu D; Park BH Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157 [TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer. Vlataki K; Antonouli S; Kalyvioti C; Lampri E; Kamina S; Mauri D; Harissis HV; Magklara A Cells; 2023 Jun; 12(12):. PubMed ID: 37371043 [TBL] [Abstract][Full Text] [Related]
15. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data. Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327 [TBL] [Abstract][Full Text] [Related]
17. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761 [TBL] [Abstract][Full Text] [Related]
18. [Current situation and prospect of breast cancer liquid biopsy]. Zhou B; Xin L; Xu L; Ye JM; Liu YH Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622 [TBL] [Abstract][Full Text] [Related]
19. Clinical application of circulating tumor DNA in breast cancer. Chan JCH; Chow JCH; Ho CHM; Tsui TYM; Cho WC J Cancer Res Clin Oncol; 2021 May; 147(5):1431-1442. PubMed ID: 33760943 [TBL] [Abstract][Full Text] [Related]
20. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Zhang X; Ju S; Wang X; Cong H Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]